Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis

European Journal of Clinical Nutrition

Volumn 70, Issue 9, 2016, Pages 995-999

  Brola, W ^a   Sobolewski, P ^b   Szczuchniak, W ^b   Goral A ^a   Fudala, M ^a   Przybylski, W ^a,c   Opara, J ^d  

^a Department of Vascular Surgery and Angiology   (Poland)

^b Department of Neurology and Stroke Unit   (Poland)

^c JAN KOCHANOWSKI UNIVERSITY   (Poland)

^d INSTITUTE OF SPORT SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCIUM; GLATIRAMER; IMMUNOMODULATING AGENT; PHOSPHORUS; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE EXPRESSION; HEREDITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; RELAPSE; RISK FACTOR; SUNLIGHT; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DISABLED PERSON; ODDS RATIO; RECURRENT DISEASE; SEASON; SEVERITY OF ILLNESS INDEX; SEX FACTOR; STATISTICAL MODEL; VITAMIN D DEFICIENCY;

ADULT; CASE-CONTROL STUDIES; DISABLED PERSONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; RECURRENCE; SEASONS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84961918581     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2016.51     Document Type: Article

References (31)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517
2. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82: 1132-1141
3. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612
4. Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV et al. Sun exposure and Vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76: 540-548
5. Sundström P, Salzer J. Vitamin D and multiple sclerosis-from epidemiology to prevention. Acta Neurol Scand 2015; 132: 56-61
6. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012; 79: 2140-2145
7. Norman AW. From Vitamin D to hormone D: fundamentals of the Vitamin D endocrine system essential for good health. Am J Clin Nutr 2008; 88: 491S-499S
8. Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z et al. Availability of 25-hydroxyVitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol 2012; 189: 5155-5164
9. Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. The Vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol Disord Drug Targets 2006; 5: 363-371
10. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015; 7: 3011-3021
11. Lagishetty V, Liu NQ, Hewison M. Vitamin D metabolism and innate immunity. Mol Cell Endocrinol 2011; 347: 97-105
12. Cannell JJ, Hollis BW. Use of Vitamin D in clinical practice. Altern Med Rev 2008; 13: 6-20
13. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
15. Kurtzke JF. On the origin of EDSS. Mult Scler Relat Disord 2015; 4: 95-103
16. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H et al. Higher 25-hydroxyVitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203
17. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of Vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14: 1-5
18. Ascherio A, Munger K, Simon C, Kappos L, Polman CH, Freedman MS et al. Serum 25-hydroxyVitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss. Mult Scler 2012; 18 (Suppl. 4): 374-375
19. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72: 234-240
20. Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306-314
21. Napiórkowska L, Budlewski T, Jakubas-Kwiatkowska W, Hamzy V, Gozdowski D, Franek E. Prevalence of low serum Vitamin D concentration in an urban population of elderly women in Poland. Pol Arch Med Wewn 2009; 119: 699-703
22. Kubicka K, Pierzchała K. Concentration of 25(OH)D3 and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study. Neurol Neurochir Pol 2013; 47: 126-130
23. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum Vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012; 79: 261-266
24. Shahbeigi S, Pakdaman H, Fereshtehnejad SM, Nikravesh E, Mirabi N, Jalilzadeh G. Vitamin D3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med 2013; 4: 585-591
25. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of Vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40: 627-639
26. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania. Australia J Neurol 2007; 254: 581-590
27. Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. Swiss Med Wkly 2011; 141: w13192
28. Kragt J, van Amerongen B, Killestein J, Dijkstra C, Uitdehaag B, Polman C et al. Higher levels of 25-hydroxyVitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15: 9-15
29. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R et al. A phase I/II dose escalation trial of Vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-1859
30. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of Vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 2013; 19: 1571-1579
31. Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after Vitamin D supplementation. Ther Adv Neurol Disord 2012; 5: 187-198